RGN (Regucalcin)

The results demonstrated consistent detection outcomes with recovery rates ranging from 93 % to 104 % and relative standard deviations (RSD) between 1.2 % and 3.7 %. This platform provides a practical and efficient tool for detecting SMP30 antibodies and holds broader application potential in tumor marker monitoring and cancer diagnosis.

Genome-wide association studies have identified RGPR-p117/SEC16B as an obesity-associated gene, suggesting RGPR-p117's involvement in lipid metabolism in obesity. This review discusses RGPR-p117's advanced role in regulating cellular processes, such as cell proliferation and lipid metabolism, as well as its relationship with obesity.

In addition, treatment with regucalcin inhibited metastatic activity, including adhesion, invasion, and migration of glioblastoma cells. Thus, extracellular regucalcin inhibited the activity of human glioblastoma cells, suggesting a suppressive role in the cancer microenvironment.

Finally, a xenograft mouse model showed that TTK significantly promotes MM development. In summary, we demonstrated that the TTK-RGN axis regulates cell apoptosis, G0/G1 phase arrest, and proliferation in MM, highlighting TTK as a potential target for therapeutic intervention in this cancer.

Alteration of the serum regucalcin levels in physiological and pathophysiological conditions may influence the activity of cancer cells in the microenvironment. This review will discuss the potential role of extracellular regucalcin in cancer cell activity as a critical suppressor in the cancer microenvironment.

A TNF-α signaling inhibitor blocked these effects. Thus, overexpressed RGPR-p117 was found to suppress the activity of breast cancer cells by regulating various signaling processes, providing new insight into cellular signaling regulation.

Bioinformatic analysis showed that the loss of RGN correlates with the development of metastatic PCa and poor survival outcomes. RGN knockdown induced a cancer-like phenotype in PNT1A cells, indicated by increased cell viability and proliferation and reduced apoptosis. In DU145 PCa cells, RGN knockdown augmented migration and enhanced the glycolytic profile, which indicates increased aggressiveness, in line with patients' data. GPER activation modulated RGN expression in PCa cells and RGN knockdown in DU145 cells influenced GPER actions, which highlighted an interplay between these molecular players with relevance for their potential use as biomarkers or therapeutic targets.

SMP30 inhibits HCC metastasis by influencing the expression of EMT-related proteins after interacting with ROCK1.

These observations and our in silico molecular docking analysis suggest that ChiC is a potential anticancer agent and is more efficient than ChiB. Since the ChiC is able to inhibit both cancer cell proliferation and migration, it could be a potential candidate for the treatment of metastatic cancer.

We discuss the possible mechanisms by which regucalcin expression is downregulated in cancer cells to facilitate understanding of how regucalcin regulates cell growth function. This mini-review may lead to better therapeutic targets with regucalcin.

The therapeutic value of regucalcin suggests its potential significance in treating cancer patients. This review delves into the most recent research on the regulatory role of regucalcin in human cancer development, providing a novel approach for treatment.

However, this was abolished by Compound C and EX-527 that specifically inhibit AMP-activated protein kinase (AMPK) and Silent Information Regulator T1 (Sirt1), respectively...These results demonstrate that, as a novel food factor, RSV-induced upregulation of SMP30 by activating AMPK/Sirt1-Foxo1 signaling and may attenuates HO-induced oxidative damage. The findings of this study offer new perspectives of the anti-ageing properties of RSV.